These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 24055775)

  • 1. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients.
    Tang C; Liu Y; Qin H; Li X; Guo W; Li J; Wang W; Qu L; Hu H; Xu C; Zheng L; Huang Y; Liu B; Gao H; Halleen JM; Liu X
    Clin Chim Acta; 2013 Nov; 426():102-7. PubMed ID: 24055775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
    Ebert W; Muley T; Herb KP; Schmidt-Gayk H
    Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.
    Korpela J; Tiitinen SL; Hiekkanen H; Halleen JM; Selander KS; Väänänen HK; Suominen P; Helenius H; Salminen E
    Anticancer Res; 2006; 26(4B):3127-32. PubMed ID: 16886645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
    Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y
    Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer.
    Salminen E; Ala-Houhala M; Korpela J; Varpula M; Tiitinen SL; Halleen JM; Väänänen HK
    Acta Oncol; 2005; 44(7):742-7. PubMed ID: 16227166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of bone metabolic markers in breast cancer with bone metastasis.
    Wada N; Fujisaki M; Ishii S; Ikeda T; Kitajima M
    Breast Cancer; 2001; 8(2):131-7. PubMed ID: 11342986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
    Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A
    Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients.
    Chao TY; Ho CL; Lee SH; Chen MM; Janckila A; Yam LT
    J Biomed Sci; 2004; 11(4):511-6. PubMed ID: 15153786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasis.
    Chao TY; Wu YY; Janckila AJ
    Clin Chim Acta; 2010 Nov; 411(21-22):1553-64. PubMed ID: 20599857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
    Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the activity of tartrate-resistant acid phosphatase isoform 5b in normal Chinese children--a novel marker for bone growth.
    Chen CJ; Chao TY; Janckila AJ; Cheng SN; Ku CH; Chu DM
    J Pediatr Endocrinol Metab; 2005 Jan; 18(1):55-62. PubMed ID: 15679069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum tartrate resistant acid phosphatase as a potential marker of bone metastasis from breast cancer.
    Wada N; Ishii S; Ikeda T; Enomoto K; Kitajima M
    Anticancer Res; 1999; 19(5C):4515-21. PubMed ID: 10650803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival markers related to bone metastases in prostate cancer.
    Salminen EK; Kallioinen MJ; Ala-Houhala MA; Vihinen PP; Tiitinen SL; Varpula M; Vahlberg TJ
    Anticancer Res; 2006; 26(6C):4879-84. PubMed ID: 17214355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M; Takahashi S; Ogata E
    Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRACP 5b and CTX as osteological markers of delayed fracture healing.
    Moghaddam A; Müller U; Roth HJ; Wentzensen A; Grützner PA; Zimmermann G
    Injury; 2011 Aug; 42(8):758-64. PubMed ID: 21168135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnostic value of bone metabolic markers ICTP and BAP in lung cancer patients with bone metastases].
    Xin Y; Han B; Lou J; Wu J; Niu Y
    Zhongguo Fei Ai Za Zhi; 2010 Oct; 13(10):947-53. PubMed ID: 20959067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Uric Acid (UA) Negatively Affects Serum Tartrate-Resistant Acid Phosphatase 5b (TRACP 5b) Immunoassay.
    Wu ZQ; Zhang Y; Xie E; Song WJ; Yang RX; Yan CJ; Zhang BF; Xu HG
    PLoS One; 2016; 11(1):e0147554. PubMed ID: 26800211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tartrate-resistant acid phosphatase 5b as serum marker of bone metabolism in cancer patients.
    Mose S; Menzel C; Kurth AA; Obert K; Breidert I; Borowsky K; Böttcher HD
    Anticancer Res; 2003; 23(3C):2783-8. PubMed ID: 12926113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study.
    Urakawa H; Ando Y; Hase T; Kikumori T; Arai E; Maeda O; Mitsuma A; Sugishita M; Shimokata T; Ikuta K; Ishiguro N; Nishida Y
    Int J Cancer; 2020 Jun; 146(12):3504-3515. PubMed ID: 31846063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
    Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
    Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.